Multiple System Atrophy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of multiple system atrophy (MSA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of MSA for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years, and the major mature pharmaceutical markets are covered in this report.
Clarivate Epidemiology’s MSA forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MSA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 3 MSA patient populations, as follows:
- Diagnosed MSA prevalent cases
- Diagnosed MSA incident cases
- Diagnosed MSA prevalent cases by UMSARS-IV disability stage
Note: Coverage may vary by country.
